Peptides for Anti-Aging: The 1990 Study That Started It

Almost every anti-aging peptide sold today traces back to a single study published in The New England Journal of Medicine in July 1990.

Rudman and colleagues gave human growth hormone to men over 60 for six months and reported increases in lean body mass and skin thickness with a decrease in adipose tissue¹. The findings were striking, widely reported, and became the founding text of an industry: if the decline of a hormone tracks aging, restoring the hormone might reverse it.

Here is what almost never gets sold alongside it: the field went on to test that idea properly, and the results did not hold up the way the 1990 paper implied. When the controlled human evidence on growth hormone in healthy participants was pooled systematically, the increase in lean body mass was attributed largely to fluid retention rather than functional muscle, there was no improvement in strength or exercise capacity, and adverse events — soft-tissue swelling, joint pain, fatigue — went up².

That is the shape of this entire category, and once you see it you will see it everywhere on this page.

The Rudman Study and Its Afterlife

It is worth being fair to the original work. It was a real study, published in a top journal, reporting real measurements. The problem is not the paper — it is everything built on top of it.

Twelve men received growth hormone. Six months. The measured outcomes were body composition and skin thickness, not strength, function, disease risk or lifespan. The study was not designed to answer whether the men were healthier, and it did not claim to.

Three decades of marketing has treated it as though it did. And when the question it did not answer was finally addressed across the accumulated controlled evidence, the answer was unfavorable². The compounds now sold for anti-aging — sermorelin, ipamorelin, CJC-1295, the GHRPs — do not even administer growth hormone directly; they ask the pituitary to release more of the hormone that failed to show functional benefit when given directly. See GH peptides and recovery and are GH peptides safe and legal.

Epitalon — and the Single-Laboratory Problem

Epitalon is the longevity peptide with the most confident claims attached — telomerase, pineal function, melatonin rhythm restoration, lifespan.

Search its human literature and a pattern appears immediately. There is work on pineal-gland peptides normalizing the daily melatonin rhythm in old monkeys and elderly people³, a review on peptides and aging⁴, and a controlled study of epitalon in retinitis pigmentosa⁵.

Look at the author lists. Khavinson appears on all of them, and the work is concentrated in a narrow set of journals. As with BPC-157's gut literature, this is not an accusation of bad faith — compounds need champions, and a single productive group is how many real discoveries begin. But independent replication is what converts a promising result into a reliable one, and here it is what is missing. A citation count measures how productive one group has been, not how many independent teams confirmed anything.

We take the compound's regulatory position separately in epitalon FDA status, and the same structural pattern appears in peptides for gut health.

GHK-Cu — Real Science, Wrong Route

GHK-Cu has the most legitimate underlying biology of anything in this category. It is a naturally occurring human tripeptide whose plasma level declines with age, with a genuine literature in tissue remodeling, collagen stimulation and gene modulation⁶.

The split that matters is route. Topically, applied to skin, GHK-Cu has real dermatological evidence and is an established cosmetic ingredient. Injected, for systemic anti-aging, it has no controlled human trial. The mechanism does not transfer across route and target tissue just because the molecule is the same — we set the whole split out in GHK-Cu (copper peptide), and cover the hair version of the same claim in peptides for hair growth.

NAD+ — the Best-Tested and Least Encouraging

NAD+ and its precursors are the anti-aging compounds with the most developed human trial record, which makes their results the most informative here even though NAD+ is a coenzyme rather than a peptide.

Nicotinamide riboside did not alter mitochondrial respiration, content or morphology in skeletal muscle in the men studied⁷ — a direct test of the mechanism, with a null result. A separate randomized trial found changes in body composition and muscle acetylcarnitine without the outcome the marketing implies⁸.

Raising a molecule in the blood is not the same as changing what happens to a person. Full assessment in NAD+ injections and peptides for energy.

The Endpoint Problem

Step back and there is a structural reason this category cannot deliver what it promises, regardless of any individual compound.

An anti-aging claim is a claim about outcomes over decades — lifespan, healthspan, disease incidence. Every study cited on every product page in this space measures something else: a biomarker, a hormone level, a body-composition scan, a skin-thickness measurement, at three or six months. Those are surrogate endpoints, and the history of medicine is substantially a history of surrogate endpoints that moved while the outcome did not.

This is not a technicality. It is why the 1990 study could report genuine changes in body composition and still not establish that anyone was better off — a gap the pooled evidence later made explicit². A trial that could actually settle an anti-aging claim would need decades and thousands of participants, and nobody selling a subscription has run one.

Thymalin, Thymosin and the Rest of the Menu

A few more names appear on longevity menus and deserve placing, because each one repeats a pattern already covered above rather than introducing a new kind of evidence.

Thymalin and the thymic peptides come from the same research tradition as epitalon, with the same concentration of authorship and the same absence of independent replication.

Thymosin alpha-1 is the exception worth knowing about — it has a genuine clinical history in immune indications, which is a different and better-supported claim than longevity. We cover it in thymosin alpha-1 and immunity.

MOTS-c and SS-31 are sold as longevity compounds via the mitochondrial route. Their evidence is covered in peptides for energy — including a Phase 3 trial of elamipretide that did not meet its primary endpoints, and the finding that endurance training raises MOTS-c rather than the other way round.

5-amino-1MQ is not a peptide but sits on the same shelf, sold as the oral route to raising NAD+. See 5-amino-1MQ: the evidence.

The consistent shape: a mechanism that is real, a surrogate endpoint that moved, and an outcome nobody measured.

What This Costs

Longevity peptides are among the most expensively packaged products in the market.

ElitePhysiqMD prices epithalon at $233.10 a month and GHK-Cu at $299.70, on a peptide page whose homepage advertises the category "from $161/mo" — a floor no product on the menu meets. Live Vital advertises NAD+ at "$83/mo" against a ten-week protocol totaling $249, nearer $108 a month. Hone Health's sermorelin page shows "$130/mo" against a real $285, because the product requires a $155 membership. MadeMed publishes prices but offers no monthly option at all — the cheapest way in is a single charge covering three months, with an IGF-1 blood test you arrange and pay for yourself.

Boards: best NAD+ injection providers, best sermorelin providers, all on the rankings index with figures in the price transparency index.

Bottom Line

The anti-aging peptide industry rests on a 1990 study of twelve men that measured body composition and skin thickness over six months¹ — and on the fact that most people never encounter what came afterward, which is that pooled controlled evidence found the lean-mass gain was largely fluid, with no strength or exercise-capacity benefit and more adverse events².

Epitalon's human literature comes overwhelmingly from one research group³⁴⁵. GHK-Cu's real evidence is topical rather than injected⁶. NAD+ precursors failed a direct test of the mechanism they are sold on⁷⁸.

And structurally, every study in this space measures a surrogate at three or six months while the claim is about decades. That gap is not something a better compound fixes; it is the shape of the problem.

None of this means aging biology is fake — it is one of the most interesting fields in science. It means the products sold ahead of the evidence are sold ahead of the evidence. For how each compound grades against human data, see what are peptides good for, 5-amino-1MQ and the research library.